Takeda, Eli Lilly Partner To Sell Evista In Seven Asian Nations
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and Eli Lilly have formed a partnership in which the Japanese maker is to market and distribute Evista (raloxifene)
Takeda Pharmaceutical and Eli Lilly have formed a partnership in which the Japanese maker is to market and distribute Evista (raloxifene). The drug for treating osteoporosis in women who have reached menopause is to be sold by Takeda in seven Asian markets, also for reducing the risk of breast cancer in three of them. The former purpose is in Hong Kong, Macau, Malaysia, the Philippines, Singapore, South Korea and Thailand, the latter in the Philippines, Singapore and Thailand. (Click here for more) "Takeda Enters Into Partnership to Distribute Evista" - Asahi Shimbun (Japan) (6/4/11) |